Dianthus Historical Income Statement
| DNTH Stock | 28.03 0.06 0.21% |
Historical analysis of Dianthus Therapeutics income statement accounts such as Selling General Administrative of 14.9 M or Selling And Marketing Expenses of 443.3 K can show how well Dianthus Therapeutics performed in making a profits. Evaluating Dianthus Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Dianthus Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Dianthus Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Dianthus Therapeutics is a good buy for the upcoming year.
Dianthus |
About Dianthus Income Statement Analysis
Dianthus Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Dianthus Therapeutics shareholders. The income statement also shows Dianthus investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Dianthus Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Dianthus Therapeutics. It is also known as Dianthus Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Dianthus Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Dianthus Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.As of now, Dianthus Therapeutics' Selling And Marketing Expenses is increasing as compared to previous years. The Dianthus Therapeutics' current Gross Profit is estimated to increase to about 2.6 M, while Depreciation And Amortization is projected to decrease to under 337.2 K.
| 2021 | 2023 | 2024 (projected) | Interest Expense | 3.6M | 4.1M | 2.7M | Depreciation And Amortization | 2.0M | 355K | 337.3K |
Dianthus Therapeutics income statement Correlations
Click cells to compare fundamentals
Dianthus Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Dianthus Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 1.8M | 2.0M | 2.0M | 147K | 355K | 337.3K | |
| Selling General Administrative | 23.8M | 28.1M | 2.0M | 6.7M | 18.2M | 14.9M | |
| Gross Profit | (1.8M) | (2.0M) | (544K) | 6.3M | 2.5M | 2.6M | |
| Other Operating Expenses | 83.0M | 78.7M | 14.6M | 36.1M | 51M | 50.6M | |
| Operating Income | (83.0M) | (78.7M) | (13.1M) | (29.7M) | (48.2M) | (50.6M) | |
| Ebit | (83.0M) | (78.7M) | (15.1M) | (29.8M) | (48.2M) | (50.6M) | |
| Research Development | 57.4M | 48.6M | 12.6M | 29.4M | 32.8M | 35.2M | |
| Ebitda | (81.1M) | (76.7M) | (13.1M) | (29.7M) | (47.8M) | (50.2M) | |
| Cost Of Revenue | 1.8M | 2.0M | 2.0M | 147K | 355K | 337.3K | |
| Total Operating Expenses | 81.1M | 76.7M | 14.6M | 36.1M | 50.6M | 49.9M | |
| Income Before Tax | (76.8M) | (74.9M) | (13.1M) | (28.5M) | (43.6M) | (45.7M) | |
| Total Other Income Expense Net | 6.2M | 3.8M | (26K) | 84K | 4.6M | 2.4M | |
| Net Income | (76.8M) | (74.9M) | (13.1M) | (28.5M) | (43.6M) | (45.7M) | |
| Income Tax Expense | 6.2M | 7.5M | (2.0M) | (1.3M) | 187.1K | 177.8K |
Currently Active Assets on Macroaxis
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.93) | Revenue Per Share 0.2 | Quarterly Revenue Growth 0.923 | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.